which mostly occurs in older adults, is characterized by large fluid-filled blisters on the skin which can be itchy and painful, reddening of the skin and painful lesions. If approved for BP, Dupixent will become the first medicine approved as a targeted treatment for BP in the United...
In the US, Dupixent is already approved for the treatment of adults priced around $37,000 per patient per year, but had some bad press lately as Amgen sued Sanofi and Regeneron over the drug back in April claiming patient infringement. In Europe the CHMP’s decisions almost always translate...